Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP)
Quality of Evidence:
Coadministration has not been studied. A clinically significant effect on amiodarone is unlikely as it is metabolised by CYP3A4 and amiodarone is unlikely to affect concentrations of emtricitabine. However, amiodarone is an inhibitor of P-gp and could potentially increase the absorption of tenofovir-DF, thereby increasing the systemic concentrations of tenofovir. Monitoring of tenofovir-associated adverse reactions, including frequent renal monitoring, is recommended.
View all available interactions with
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP) by clicking